Flow cytometric immunophenotyping of cerebrospinal fluid.
Leptomeningeal disease is an important adverse complication occurring in patients with B and T cell lymphomas and acute leukemias of lymphoid and myeloid origin. Recent reports suggest that multiparameter flow cytometry immunophenotypic assessment of spinal fluid samples could improve the efficiency of detection of CNS involvement, due to its high specificity and greater sensitivity. However, spinal fluid samples are frequently paucicellular with a rapidly decreasing cell viability. Staining of spinal fluid therefore requires dedicated sample storage/transport, staining, and preparation protocols. The Basic Protocol in this unit outlines a consensus multiparameter (3- to 8-color) flow cytometry immunophenotypic protocol for the evaluation of CNS involvement of cerebrospinal fluid (CSF) samples by neoplastic cells. A Support Protocol describing the simultaneous assessment of surface and cytoplasmic antigens is also provided. Finally, in the Alternate Protocol, we describe a method to calculate absolute numbers of both normal and pathological cell subpopulations by adding counting beads to the assay.
Kraan
Jaco
J
Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands.
Gratama
Jan W
JW
Haioun
Corinne
C
Orfao
Alberto
A
Plonquet
Anne
A
Porwit
Anna
A
Quijano
Sandra
S
Stetler-Stevenson
Maryalice
M
Subira
Dolores
D
Wilson
Wyndham
W
D000818:Animals; D000954:Antigens, Surface / Q000032:analysis; D002555:Cerebrospinal Fluid / Q000166:cytology*; D005434:Flow Cytometry / Q000379:methods*; D006801:Humans; D016130:Immunophenotyping / Q000379:methods; D007938:Leukemia / Q000150:complications / Q000473:pathology; D008223:Lymphoma / Q000150:complications / Q000473:pathology; D008577:Meningeal Neoplasms / Q000175:diagnosis
D000954:Antigens, Surface
J Neurooncol. 1990 Dec;9(3):225-9
2086737
Clin Lab Haematol. 2006 Feb;28(1):22-9
16430456
Am J Clin Pathol. 2002 Jun;117(6):952-8
12047148
Ann Neurol. 1995 Jul;38(1):51-7
7611725
Neurology. 1979 Oct;29(10):1369-75
573381
Diagn Cytopathol. 1999 Nov;21(5):313-8
10527476
Ann Oncol. 2002 Jul;13(7):1099-107
12176790
Acta Oncol. 1996;35(6):703-8
8938217
Neurology. 2002 Feb 12;58(3):339-40
11839828
Diagn Cytopathol. 2002 Nov;27(5):271-5
12411991
Am J Clin Pathol. 1998 Sep;110(3):341-6
9728609
Diagn Cytopathol. 2000 Dec;23(6):369-74
11074639
Cancer. 1982 Feb 15;49(4):759-72
6895713
Ann Oncol. 2004 Jan;15(1):129-33
14679132
Hematol Oncol Clin North Am. 2005 Aug;19(4):597-609, v
16083825
J Clin Oncol. 1996 Mar;14(3):941-4
8622043
Blood. 2005 Jan 15;105(2):496-502
15358629
Blood. 1998 Feb 15;91(4):1178-84
9454747
J Neuroimmunol. 2008 Mar;195(1-2):164-70
18358542
Neurology. 2007 May 15;68(20):1674-9
17502548
Hematol Oncol Clin North Am. 2005 Aug;19(4):751-63, viii
16083835
Cancer. 2006 Jun 25;108(3):157-62
16649227
Cytometry. 1996 Mar 15;26(1):16-21
8809476
Blood. 1997 Sep 15;90(6):2465-70
9310499